Clinical trials: Functional Disorder
Cataracts, Meibomian Gland Dysfunction (MGD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative…
- Trial name
- NCT03708367
- Testing
- LipiFlow Thermal Pulsation System
- Where
- 5 sites in United States
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Healthy, Renal Impairment
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects.
- Trial name
- NCT01761773
- Testing
- cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Exelixis
Erectile Dysfunction
Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction
Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label, fixed dose, 6-month extension study (parent study : DA8159_EDD_III)
- Trial name
- NCT01901640
- Testing
- DA-8159 (Udenafil)
- Volunteers
- 302 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Alzheimers Disease
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 2 (NCT07170150)
- Testing
- Trontinemab
- Where
- 147 sites in United States, Argentina and 14 more
- Volunteers
- 1,060 people
- Sponsor
- Hoffmann-La Roche
Solid Tumours
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally
- Trial name
- NCT00483860
- Testing
- Topotecan
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy
The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction.
- Trial name
- NCT00874679
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 15 sites in China, Croatia and 13 more
- Volunteers
- 7,293 people
- Sponsor
- Bayer
Chronic Constipation
A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation
The purpose of this study is to evaluate the efficacy and safety of titrated KWA-0711 dose in chronic constipation patients.
- Trial name
- NCT01938196
- Testing
- KWA-0711
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Systolic Left Ventricular Dysfunction
The C-MIC-II Follow-Up Study
The C-MIC System is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart.
- Trial name
- C-MIC-II-FU (NCT05189860)
- Testing
- C-MIC system
- Where
- 6 sites in Bosnia and Herzegovina, Croatia and 2 more
- Volunteers
- 31 people
- Sponsor
- Berlin Heals GmbH
Safety, Peripheral Neuropathy
Xanamem™ in Healthy Elderly Subjects
Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body.
- Conditions
- Safety, Peripheral Neuropathy, Cortisol, Central Nervous System
- Trial name
- XanaHES (NCT03830762)
- Testing
- Xanamem
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Erectile Dysfunction (ED)
Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction
This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction.
- Trial name
- UNITED (NCT07273773)
- Testing
- Rigicon Infla10® Inflatable Penile Prosthesis (IPP)
- Where
- 4 sites in United States
- Volunteers
- 182 people
- Sponsor
- Rigicon, Inc.
Metabolic Dysfunction-Associated Steatohepatitis
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07859813
- Testing
- ARO-INHBE
- Volunteers
- 252 people
- Sponsor
- Arrowhead Pharmaceuticals
Brain Injuries, Traumatic
HITT Device Pilot Testing for Traumatic Brain Injury
The purpose of this research study is to collect data from the eyes of traumatic brain injury (TBI) patients. Patients will look at a green target that will measure the fixation of the eye for 30 seconds.
- Trial name
- NCT03249818
- Testing
- HITT device
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rebiscan, Inc.
Erectile Dysfunction
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
- Trial name
- NCT00667979
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Volunteers
- 264 people
- Sponsor
- Bayer
Ischaemic Stroke
The RETRAIN Trial Phase 2
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom.
- Trial name
- RETRAIN 2 (NCT07197996)
- Testing
- Intermittent Pneumatic Compression, geko® T3
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- Firstkind Ltd
Stroke, Attention Disorder
Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting…
- Trial name
- NCT05728840
- Testing
- Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities
- Where
- Switzerland
- Volunteers
- 135 people
- Sponsor
- Mindmaze SA
Bradycardia
Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker
The IBSY04 clinical investigation is an European, prospective, multi-centre, non-randomized, longitudinal study.
- Trial name
- DREAM (NCT01537718)
- Testing
- REPLY 200
- Where
- 5 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- LivaNova
COPD
Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)
The aim of the study is to compare the effect of roflumilast on lung function in patients with COPD. Roflumilast will be administered orally once daily in the morning at one dose level.
- Trial name
- NCT00242320
- Testing
- Roflumilast
- Where
- 32 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 551 people
- Sponsor
- AstraZeneca
Friedreich Ataxia, Cardiomyopathies
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
The goal of this clinical trial is to learn how ATI-105 administered to healthy participants at works in the body at different doses and with or without food.
- Conditions
- Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases
- Trial name
- NCT07869654
- Testing
- ATI-105
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Adjuvia Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim